News update in Aequs has just approved equity infusion

Aequs has just approved a ₹650 crore equity infusion via promoter warrants to expand its aerospace and consumer businesses, including its Hosur facility. This move will increase promoter holding to 60.73% and strengthen the company’s ability to raise borrowings for future growth. 🔑 Key Highlights Equity Infusion: ₹650 crore through preferential warrants issued to Mellwood Trustee Services, part of the Melligeri Private Family Foundation. Payment Terms: ₹325 crore upfront (twice the regulatory minimum), balance payable upon warrant exercise within 18 months. Promoter Holding: Will rise from 59.09% to 60.73% after full conversion. Expansion Focus: Aerospace and consumer manufacturing, especially the Hosur facility, subsidiaries, and joint ventures. Timeline: Conversion into shares and full payment expected by December 31, 2027. 📊 Financial & Market Context Aspect Details Order Book Aerospace order book crossed USD 1 billion in Q1 FY27, up 13% sequentially. Revenue Growth Q1 FY27 consolidated revenue: ₹3,955 million, up 55% YoY. Consumer Segment Revenue surged 190% YoY to ₹734 million, now contributing 19% of total revenue. Equity Price Warrants priced at ₹231.55 per share, based on VWAP calculations. 📌 Strategic Implications Aerospace Growth Engine: Strong demand and customer confidence are driving program wins faster than expected. Consumer Manufacturing Scale-Up: Rapid expansion in electronics and consumer goods manufacturing is diversifying revenue streams. Capital Structure: The infusion provides a base for raising term borrowings, ensuring liquidity for aggressive expansion. Shareholder Approval: An Extraordinary General Meeting (EGM) is scheduled for October 22, 2026, to seek shareholder nod. ⚠️ Risks & Considerations Regulatory Approvals: Expansion plans hinge on SEBI and shareholder clearances. Execution Risk: Scaling aerospace and consumer facilities requires timely commissioning and cost control.